Shanghai, China - On December 1, the Toumai® Remote Surgical System received full-department clinical approval from India’s Central Drugs Standard Control Organisation (CDSCO).

To date, the MicroPort® MedBot’s Toumai® Remote Surgical System has received market approval in nearly 10 countries, including China, India, and Brazil, and was also granted Investigational Device Exemption (IDE) approval by the U.S. FDA.

These milestones extend the system’s coverage to regions representing over 40% of the world’s population.

To support large-scale deployment, MicroPort® MedBot has developed an advanced remote surgery technology architecture featuring ultra-low-latency imaging, encrypted data transmission, dynamic network optimization, and multilayer safety assurance.

Toumai® is currently the world’s only commercial remote robotic surgery system with full-department, full-procedure capability. To date, it has supported over 700 procedures across 20+ countries and regions, maintaining a 100% procedural success rate and setting more than 60 world records across performance dimensions.

In December, two cross-border urologic surgeries were successfully performed from China to India using Toumai®, with national media highlighting the system’s real-time responsiveness, stability, and precision, comparable to in-person robotic surgery.